Diabetic Retinopathy – Regeneron VEGF Trap-Eye for DME

Regeneron and Bayer HealthCare are studying an investigational new compound, VEGF Trap-Eye (aflibercept ophthalmic solution) in the treatment of diabetic macular edema. The experimental compound has proved effective through clinical trials in patients with wet AMD and retinal vein occlusion. Phase 3 clinical trials are underway in the United States and other countries for patients with diabetic macular edema.